US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% SNDK $1,704.16 ▼-0.92% AAPL $332.89 ▼-0.24%
FinancialContent

Crescita Therapeutics Inc (TSX:CTX)

0.7900 UNCHANGED
Last Price Updated: 9:30 AM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crescita Therapeutics Inc

< Previous 1 2 Next >
News headline image
Crescita Therapeutics Inc. Announces Closing of Arrangement
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Therapeutics Inc. Announces Final Consideration Payable to Shareholders Pursuant to Arrangement with ClinActiv
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Therapeutics Inc. Obtains Final Order Approving Plan of Arrangement
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Obtains Shareholder Approval To Be Acquired By ClinActiv Holdings
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Reports First Quarter 2026 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Reports Q4 and Fiscal 2025 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Announces Definitive Agreement to Be Acquired by ClinActiv Holdings in an All-Cash Transaction at a Significant Premium
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Reports Third Quarter 2025 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Reports Second Quarter 2025 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis®
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports First Quarter 2025 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Reports Q4 and Fiscal 2024 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports Third Quarter 2024 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
From Crescita Therapeutics
Via Business Wire
News headline image
Keynotes and 50 Companies to Present at the Planet MicroCap Showcase: VANCOUVER in association with Small Cap Discoveries on September 25-26, 2024 at the Fairmont Waterfront Vancouver
Via ACCESSWIRE
News headline image
Crescita to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in Association with Small Cap Discoveries on Thursday, September 26, 2024
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports Second Quarter 2024 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years
From Crescita Therapeutics
Via Business Wire
News headline image
Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery Device
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Completes Acquisition of Strategic Assets of Occy Laboratory
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita to Acquire Strategic Assets of Occy Laboratory
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports First Quarter 2024 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports Q4 and Fiscal 2023 Results
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports Third Quarter 2023 Results
From Crescita Therapeutics Inc.
Via Business Wire
News headline image
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
From Crescita Therapeutics
Via Business Wire
News headline image
Crescita Reports Second Quarter 2023 Results
From Crescita Therapeutics
Via Business Wire
< Previous 1 2 Next >